Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways (NCT07469384) | Clinical Trial Compass
RecruitingNot Applicable
Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways
United States120 participantsStarted 2026-02-01
Plain-language summary
This study investigates the ability of transcranial direct current stimulation (tDCS) applied over the motion processing area of the brain (area MT) to improve face emotion recognition (FER) ability. tDCS is a type of non-invasive brain stimulation in which low level currents are applied over the scalp to influence underlying brain function. In schizophrenia, impaired ability to detect facial motion has been shown to contribute to impaired FER, which, in turn, leads to difficulties in social cognition and poor social outcome. The study will use both fMRI and EEG to measure brain function while participants view moving dot and dynamic face stimuli. Analyses will compare changes in fMRI and EEG activity in individuals receiving active vs. sham stimulation.
Who can participate
Age range18 Years – 55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male or female subject, age 18-55
✓. Competent and willing to sign informed consent
✓. No more than moderately ill
✓. SCID DSM-5 diagnosis of Sz/SzAff
✓. WAIS IQ \>70
✓. Does not meet current criteria for DSM-5 defined substance abuse or dependence or have a history of diagnosis within past 6 months
✓. On medication within clinically approved range
✓. Does not meet criteria for another DSM-5 disorder other than those judged to be minor (e.g. simple phobia)
Exclusion criteria
✕. Significant neurological illness or history of significant head trauma
✕. Unstable physical illness or significant auditory/visual deficits that might interfer
What they're measuring
1
MT+ activation as determined using fMRI
Timeframe: Simultaneously with the administration of the active or sham tDCS intervention during study day 10
2
MT+ activation as determined using event-related potentials (ERP)
Timeframe: Simultaneously with the administration of the active or sham tDCS intervention during study day 3
Trial details
NCT IDNCT07469384
SponsorNathan Kline Institute for Psychiatric Research
. Contraindication to MRI (e.g. metal implants, claustrophobia, pregnancy)
✕. Contraindications to tDCS including metal implant, pacemaker, history of seizure, traumatic brain injury or stroke
✕. Significant risk for suicide
✕. Has a history of an illness, disease, condition injury, or disability which, in the opinion of the principal investigator, may interfere with the completion of all study requirements per protocol, impact the quality of the data, or the validity of the study results, including unstable physical illness, significant neurological illness, significant head trauma
✕. Moderate or greater DSM-5 current substance use disorder, defined based on the presence of 4 or more of 11 substance use criteria within the past 12 months. In addition, individuals for whom substance use leads to not being able to perform work, home or school activities